<DOC>
	<DOCNO>NCT02374060</DOCNO>
	<brief_summary>To evaluate relative efficacy three commonly utilized regional corticosteroid regional treatment uveitic macular edema : periocular triamcinolone acetonide ; intravitreal triamcinolone acetonide ; intravitreal dexamethasone implant . The primary efficacy measure percent change central subfield thickness measure OCT 8 week . Participants continue study 24 week order evaluate relative effect 3 treatment strategy duration treatment effect , requirement additional injection , adverse effect .</brief_summary>
	<brief_title>PeriOcular INTravitreal Corticosteroids Uveitic Macular Edema Trial</brief_title>
	<detailed_description>Macular edema common structural complication lead cause visual loss patient uveitis . Regional injection corticosteroid frequently use treatment specifically uveitic macular edema lack high quality evidence guide choice drug ( e.g. , triamcinolone acetonide , dexamethasone ) route administration ( e.g . periocular , intravitreal ) . The question approach regional treatment uveitic macular edema key question ophthalmologist treat patient . The Periocular Intravitreal Corticosteroids Uveitic Macular Edema ( POINT ) Trial randomize trial design compare relative efficacy three regional corticosteroid commonly utilized initial regional treatment uveitic macular edema , periocular triamcinolone ( Kenalog® , Bristol-Myers Squibb Company , Princeton , NJ ) , intravitreal triamcinolone ( Triesence™ , Alcon Pharmaceuticals , Fort Worth , TX ) , intravitreal dexamethasone implant ( Ozurdex® , Allergan , Irvine CA ) conduct MUST Research Group clinical center throughout U.S. one Australia UK . After sign informed consent undergo eligibility evaluation , eligible patient randomize one three study treatment administer first study visit . Randomization participant , eye meet eligibility requirement eye receive assign treatment . The design outcome percent change central subfield macular thickness OCT baseline 8 week visit . After assessment primary outcome 8 week , second injection best medical judgment use macular edema improve follow : Eye ( ) meeting trial eligibility criterion receive initial injection assign treatment P01 visit . Second injection assign treatment permit 8 week visit periocular triamcinolone intravitreal triamcinolone 12 week visit intravitreal dexamethasone - Eye meet improvement definition ( 20 % decrease central subfield thickness macula ) - Eye normal central subfield thickness cystoid space 1 mm central subfield - ME worse initial improvement And follow repeat injection criterion meet : • IOP ≤21 mm Hg treatment ≤3 IOP-lowering agent ; Eyes demonstrate improvement worsen ME measured central submacular thickness OCT ( week 12 periocular intravitreal triamcinolone arm week 20 intravitreal dexamethasone arm ) consider primary treatment non-responders .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Eye level inclusion criterion least one eye must meet following condition : Noninfectious anterior , intermediate , posterior panuveitis ; either active inactive uveitis acceptable ; Macular edema ( ME ) define presence central subfield macular thickness great normal range OCT machine use , regardless presence cyst , assess study ophthalmologist ; Best correct visual acuity ( BCVA ) 5/200 good ; Baseline intraocular pressure &gt; 5 mm Hg ≤ 21 mm Hg ( current use 3 few intraocular pressurelowering medication and/or prior glaucoma surgery acceptable ) ; Baseline fluorescein angiogram gradable leakage central subfield Pupillary dilation sufficient allow OCT test . Patient level exclusion criterion : History infectious uveitis , scleritis , keratitis , infectious endophthalmitis either eye ; History central serous retinopathy either eye ; For woman childbearing potential : pregnancy , breastfeeding , positive pregnancy test ; unwilling practice adequate birth control method ( abstinence , combination barrier spermicide , hormonal ) duration trial ; Use oral acetazolamide systemic carbonic anhydrase inhibitor baseline ; Oral prednisone dose &gt; 10 mg per day ( alternative corticosteroid dose higher equipotent prednisone 10 mg per day ) OR oral prednisone dose ≤ 10 mg per day stable least 4 week ( note patient oral prednisone baseline ( P01 visit ) , dose stability requirement past 4 week apply ) ; Systemic immunosuppressive drug therapy stable least 4 week ; Known allergy hypersensitivity component study drug ; Eye level exclusion criterion least one eye meet inclusion criterion follow condition : History severe glaucoma define optic nerve damage ( cup/disc ratio ≥ 0.9 notching optic nerve rim ) ; Media opacity cause inability ass fundus perform OCT ; Presence epiretinal membrane note clinically OCT per judgment study ophthalmologist may significant enough limit improvement ME ( i.e. , cause substantial wrinkle retinal surface ) 81 ; Torn rupture posterior lens capsule ; Presence silicone oil ; Periocular intravitreal corticosteroid injection past 8 week ; Injection dexamethasone intravitreal implant past 12 week ; Placement fluocinolone acetonide implant ( Retisert ) past 3 year ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>